Joint Graduate Program in Toxicology, Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Piscataway, New Jersey.
Rutgers Institute for Translational Medicine and Science, New Brunswick, New Jersey; and.
Am J Respir Cell Mol Biol. 2023 Jan;68(1):39-48. doi: 10.1165/rcmb.2021-0495OC.
Bronchomotor tone modulated by airway smooth muscle shortening represents a key mechanism that increases airway resistance in asthma. Altered glucose metabolism in inflammatory and airway structural cells is associated with asthma. Although these observations suggest a causal link between glucose metabolism and airway hyperresponsiveness, the mechanisms are unclear. We hypothesized that glycolysis modulates excitation-contraction coupling in human airway smooth muscle (HASM) cells. Cultured HASM cells from human lung donors were subject to metabolic screenings using Seahorse XF cell assay. HASM cell monolayers were treated with vehicle or PFK15 (1-(Pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one), an inhibitor of PFKFB3 (PFK-1,6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) that generates an allosteric activator for glycolysis rate-limiting enzyme PFK1 (phosphofructokinase 1), for 5-240 minutes, and baseline and agonist-induced phosphorylation of MLC (myosin light chain), MYPT1 (myosin phosphatase regulatory subunit 1), Akt, RhoA, and cytosolic Ca were determined. PFK15 effects on metabolic activity and contractile agonist-induced bronchoconstriction were determined in human precision-cut lung slices. Inhibition of glycolysis attenuated carbachol-induced excitation-contraction coupling in HASM cells. ATP production and bronchodilator-induced cAMP concentrations were also attenuated by glycolysis inhibition in HASM cells. In human small airways, glycolysis inhibition decreased mitochondrial respiration and ATP production and attenuated carbachol-induced bronchoconstriction. The findings suggest that energy depletion resulting from glycolysis inhibition is a novel strategy for ameliorating HASM cell shortening and bronchoprotection of human small airways.
气道平滑肌缩短所调节的支气管张力代表了增加哮喘气道阻力的关键机制。炎症和气道结构细胞中葡萄糖代谢的改变与哮喘有关。尽管这些观察结果表明葡萄糖代谢与气道高反应性之间存在因果关系,但机制尚不清楚。我们假设糖酵解调节人气道平滑肌(HASM)细胞的兴奋-收缩偶联。使用 Seahorse XF 细胞分析对来自人类肺供体的培养 HASM 细胞进行代谢筛选。用载体或 PFK15(1-(吡啶-4-基)-3-(喹啉-2-基)丙烯-2-酮)处理 HASM 细胞单层,PFKFB3(磷酸果糖激酶 1,6-二磷酸果糖-2-激酶/果糖-2,6-二磷酸酶 3)的抑制剂,产生糖酵解限速酶 PFK1(磷酸果糖激酶 1)的别构激活剂,用于 5-240 分钟,并确定基础状态和激动剂诱导的 MLC(肌球蛋白轻链)、MYPT1(肌球蛋白磷酸酶调节亚基 1)、Akt、RhoA 和细胞质 Ca 的磷酸化。在人离体肺切片中测定 PFK15 对代谢活性和收缩性激动剂诱导的支气管收缩的影响。糖酵解抑制减弱了 HASM 细胞中乙酰胆碱诱导的兴奋-收缩偶联。糖酵解抑制也减弱了 ATP 产生和收缩性激动剂诱导的 cAMP 浓度。在人类小气道中,糖酵解抑制降低了线粒体呼吸和 ATP 产生,并减弱了乙酰胆碱诱导的支气管收缩。这些发现表明,糖酵解抑制导致的能量耗竭是改善 HASM 细胞缩短和保护人小气道的一种新策略。